Gilead’s Plan? Cash In on CAR-T – Motley Fool
STAT |
Gilead's Plan? Cash In on CAR–T
Motley Fool The Swiss biopharma Goliath Novartis is the only other drug developer to have a CAR–T that's pending approval from the FDA. In Kite Pharma's case, it's awaiting an FDA decision on axi-cel, a CAR–T that's under priority review for use in patients with B … Gilead just handed a revolutionary kind of cancer treatment a $12 billon endorsement Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapy The Promising New Cancer Treatment Behind Gilead's $11 Billion Deal |
